EP3500261A4 - Pulvérisation de naloxone liquide - Google Patents

Pulvérisation de naloxone liquide Download PDF

Info

Publication number
EP3500261A4
EP3500261A4 EP17841883.6A EP17841883A EP3500261A4 EP 3500261 A4 EP3500261 A4 EP 3500261A4 EP 17841883 A EP17841883 A EP 17841883A EP 3500261 A4 EP3500261 A4 EP 3500261A4
Authority
EP
European Patent Office
Prior art keywords
naloxone spray
liquid
liquid naloxone
spray
naloxone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP17841883.6A
Other languages
German (de)
English (en)
Other versions
EP3500261A1 (fr
Inventor
Kiran AMANCHA
Shivani CHILAMPALLI
Thrimoorthy Potta
Ningxin YAN
Venkat R. Goskonda
Eshwaran Narayanan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hikma Pharmaceuticals USA Inc
Original Assignee
Hikma Pharmaceuticals USA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/238,909 external-priority patent/US10722510B2/en
Priority claimed from US15/601,331 external-priority patent/US10617686B2/en
Application filed by Hikma Pharmaceuticals USA Inc filed Critical Hikma Pharmaceuticals USA Inc
Publication of EP3500261A1 publication Critical patent/EP3500261A1/fr
Publication of EP3500261A4 publication Critical patent/EP3500261A4/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP17841883.6A 2016-08-17 2017-08-10 Pulvérisation de naloxone liquide Pending EP3500261A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15/238,909 US10722510B2 (en) 2014-07-08 2016-08-17 Liquid naloxone spray
US15/601,331 US10617686B2 (en) 2014-07-08 2017-05-22 Liquid naloxone spray
PCT/US2017/046198 WO2018034920A1 (fr) 2016-08-17 2017-08-10 Pulvérisation de naloxone liquide

Publications (2)

Publication Number Publication Date
EP3500261A1 EP3500261A1 (fr) 2019-06-26
EP3500261A4 true EP3500261A4 (fr) 2020-05-06

Family

ID=61197156

Family Applications (1)

Application Number Title Priority Date Filing Date
EP17841883.6A Pending EP3500261A4 (fr) 2016-08-17 2017-08-10 Pulvérisation de naloxone liquide

Country Status (7)

Country Link
EP (1) EP3500261A4 (fr)
JP (2) JP7114570B2 (fr)
CN (1) CN109922805A (fr)
AU (1) AU2017312811B2 (fr)
CA (1) CA3033897C (fr)
MA (1) MA45995A (fr)
WO (1) WO2018034920A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3108245B1 (fr) 2014-02-18 2020-07-22 Robert I. Henkin Procédés et compositions permettant de diagnostiquer et de traiter une perte et/ou une distorsion du goût ou de l'odorat
CN109922805A (zh) * 2016-08-17 2019-06-21 因塞斯发展股份有限公司 液体纳洛酮喷雾
US20180193332A1 (en) * 2017-10-09 2018-07-12 Adapt Pharma Operations Limited Low-temperature stable opioid antagonist solutions
US11129795B2 (en) 2019-02-21 2021-09-28 Pharmaceutical Productions, Inc. Naloxone formulations for sublingual and/or buccal administration
CN112138250B (zh) * 2019-06-28 2023-04-14 四川普锐特药业有限公司 保持给药均一度的药物流体分配器及右美托咪定鼻喷器
EP4100012A4 (fr) * 2020-02-05 2024-02-07 Summit Biosciences Inc. Produits médicamenteux destinés à être administrés par voie intranasale et utilisations associées
AU2023205128A1 (en) * 2022-01-06 2024-07-25 Cyrano Therapeutics, Inc. Improved nasal administration of parkinson's therapeutics

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1575795A (zh) * 2003-06-25 2005-02-09 中国人民解放军军事医学科学院毒物药物研究所 盐酸纳洛酮鼻腔喷雾剂
US20160199294A1 (en) * 2014-07-08 2016-07-14 Insys Development Company, Inc. Sublingual naloxone spray

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US14730A (en) 1856-04-22 Improvement in corn-harvesters
US585A (en) 1838-01-27 Apparatus for extinguishing sparks in the chimneys oe steam-boilers
US8627816B2 (en) * 2011-02-28 2014-01-14 Intelliject, Inc. Medicament delivery device for administration of opioid antagonists including formulations for naloxone
SG194927A1 (en) * 2011-05-13 2013-12-30 Euro Celtique Sa Intranasal pharmaceutical dosage forms comprising naloxone
CA2834327C (fr) * 2011-09-19 2017-05-30 Orexo Ab Nouvelle composition pharmaceutique resistante a l'utilisation abusive pour le traitement d'une dependance aux opioides
US8940052B2 (en) 2012-07-26 2015-01-27 DePuy Synthes Products, LLC Expandable implant
CA2795324C (fr) * 2012-11-09 2015-07-14 Purdue Pharma Compositions pharmaceutiques comprenant de l'hydromorphone et de la naloxone
WO2015038327A1 (fr) * 2013-09-10 2015-03-19 Insys Pharma, Inc. Spray sublingual contenant de la buprénorphine
CN103637987B (zh) * 2013-12-09 2015-12-02 韩彬 羟考酮的液体药物组合物
EP3082816B1 (fr) 2013-12-20 2019-03-20 Indivior UK Limited Compositions de naloxone intranasales et leurs procédés de préparation et d'utilisation
US9480644B2 (en) 2014-03-14 2016-11-01 Opiant Pharmaceuticals, Inc. Nasal drug products and methods of their use
SG10202003562WA (en) 2014-03-14 2020-05-28 Opiant Pharmaceuticals Inc Nasal drug products and methods of their use
US9642848B2 (en) * 2014-07-08 2017-05-09 Insys Development Company, Inc. Sublingual naloxone spray
CN109922805A (zh) * 2016-08-17 2019-06-21 因塞斯发展股份有限公司 液体纳洛酮喷雾

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1575795A (zh) * 2003-06-25 2005-02-09 中国人民解放军军事医学科学院毒物药物研究所 盐酸纳洛酮鼻腔喷雾剂
US20160199294A1 (en) * 2014-07-08 2016-07-14 Insys Development Company, Inc. Sublingual naloxone spray

Also Published As

Publication number Publication date
EP3500261A1 (fr) 2019-06-26
MA45995A (fr) 2019-06-26
JP7455157B2 (ja) 2024-03-25
AU2017312811A1 (en) 2019-03-07
JP2022119843A (ja) 2022-08-17
AU2017312811A8 (en) 2019-03-14
WO2018034920A1 (fr) 2018-02-22
JP7114570B2 (ja) 2022-08-08
CA3033897C (fr) 2024-03-26
CN109922805A (zh) 2019-06-21
JP2019528278A (ja) 2019-10-10
AU2017312811B2 (en) 2023-03-16
CA3033897A1 (fr) 2018-02-22

Similar Documents

Publication Publication Date Title
EP3305103A4 (fr) Unité d'atomisation
EP3164221B8 (fr) Systèmes de nébulisation de liquide
AU2015242948A1 (en) Spray nozzle
EP3315035A4 (fr) Unité d'atomisation
EP3305417A4 (fr) Dispositif d'atomisation de supraparticules
GB201419803D0 (en) Spray booths
EP3239005A4 (fr) Gicleur de lave-glace
EP3105146A4 (fr) Dispositif de distribution par pulvérisation
EP3253684A4 (fr) Système de capuchon d'atomisation
EP3213822A4 (fr) Pulvérisateur de liquide de type à gâchette
EP3500261A4 (fr) Pulvérisation de naloxone liquide
EP3177146A4 (fr) Aerosol sublingual de naloxone
EP3345681A4 (fr) Injecteur de liquide à détente
EP3150287A4 (fr) Pulvérisateur de liquide du type à gâchette
ZA201805751B (en) Spray device
EP3162451A4 (fr) Pulvérisateur de liquide de à gâchette
EP3340821A4 (fr) Bonnet de douche
EP3375529B8 (fr) Dispositif de pulvérisation électrostatique
EP3210671A4 (fr) Structure d'orifice de pulvérisation
EP3225314A4 (fr) Pulvérisateur de liquide de type à gâchette
EP3395713A4 (fr) Pulvérisateur de liquide de type à gâchette
EP3272702A4 (fr) Distributeur de liquide
EP3266725A4 (fr) Buse
EP3162461A4 (fr) Buse de pulvérisation
EP3315036A4 (fr) Unité d'atomisation

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20190315

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: HIKMA PHARMACEUTICALS USA INC.

A4 Supplementary search report drawn up and despatched

Effective date: 20200402

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 9/00 20060101ALI20200328BHEP

Ipc: A61K 47/18 20170101ALI20200328BHEP

Ipc: A61K 31/485 20060101AFI20200328BHEP

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40011159

Country of ref document: HK

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230513

RAP3 Party data changed (applicant data changed or rights of an application transferred)

Owner name: HIKMA PHARMACEUTICALS USA INC.